Floatz logo

Duloxetine

Chronic Low-back Pain

University of North Carolina, Chapel HillSmall moleculePhase 4 / ApprovedActive
BB
67/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
57/ 100
Competitive Position
81/ 100

Competitive context

19 Active assets in the Chronic Low-back Pain cohort.

Asset / SponsorPhaseRating
NEPENTHE
Uskudar University
Phase 4BB
Dfn-15
Laboratorios Silanes S.A. de C.V.
Phase 3B
LEVODOPA
Northwestern University
Phase 2CCC
carbidopa
Northwestern University
Phase 2CCC
Naproxen
Northwestern University
Phase 2CCC

View all 20 →

Same molecule, other indications

Duloxetine is also rated in:

Diabetic NeuropathiesDormant
A
Indicative ·
83 / 100
View asset →
diabetic neuropathyDormant
A
Indicative ·
81 / 100
View asset →
diabetic neuropathyDormant
BBB
Indicative ·
79 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →